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Abstract: Developing a urine test to detect bladder tumours with high sensitivity and 
specificity  is  a  key  goal  in  bladder  cancer  research.  We  hypothesised  that  bladder 
cancer-specific glycoproteins might fulfill this role. Lectin-ELISAs were used to study the 
binding of 25 lectins to 10 bladder cell lines and serum and urine from bladder cancer 
patients and non-cancer controls. Selected lectins were then used to enrich glycoproteins 
from the urine of bladder cancer patients and control subjects for analysis by shotgun 
proteomics. None of the lectins showed a strong preference for bladder cancer cell lines 
over normal urothlelial cell lines or for urinary glycans from bladder cancer patients over 
those from non-cancer controls. However, several lectins showed a strong preference for 
bladder cell line glycans over serum glycans and are potentially useful for  enriching 
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glycoproteins originating from the urothelium in urine. Aleuria alantia lectin affinity 
chromatography and shotgun proteomics identified mucin-1 and golgi apparatus protein 1 
as proteins warranting further investigation as urinary biomarkers for low-grade bladder 
cancer. Glycosylation changes in bladder cancer are not reliably detected by measuring 
lectin binding to unfractionated proteomes, but it is possible that more specific reagents 
and/or a focus on individual proteins may produce clinically useful biomarkers. 
 
Keywords: bladder cancer; urine; biomarker; lectin; glycoproteome 
 
 
 
 
 
1. Introduction 
 
 
Urothelial bladder cancer is the fourth most common cancer in men and ninth most common cancer 
in women in western societies [1]. This highly heterogeneous disease presents as a spectrum from 
low-grade non-invasive tumours with a good prognosis but high recurrence rate through to high-grade 
muscle invasive tumours with a very poor prognosis. Low grade tumours tend to have a near-normal 
karyotype with few genomic rearrangements and often have activating mutations in FGFR3 and the 
MAPK pathway, whereas high-grade tumours typically have inactivating mutations in TP53 and/or 
other tumour suppressor genes and multiple chromosomal aberrations [2]. Algorithms based on 
clinicopathological factors can be used to guide treatment, which ranges from transurethral resection 
and surveillance for recurrence for low-risk disease through to cystectomy and systemic chemotherapy 
for muscle-invasive and metastatic disease [3]. 
Bladder tumours are typically detected by flexible cystoscopy, a burdensome and resource-intensive 
procedure. Patients undergoing surveillance for bladder cancer will require this procedure at regular 
intervals for many years [4]. There is thus a need for a urine or blood-based test to reduce reliance on 
cystoscopy. Despite extensive research, most candidate urinary biomarkers for bladder cancer do not 
show sufficient sensitivity and specificity to replace cystoscopy [5]. Most of the proposed biomarkers 
are  particularly  poor  at  detecting  low-grade  NMIBC.  Indeed,  no  urinary  biomarkers  have  been 
validated as having sufficient sensitivity and specificity to be widely adopted in clinical practice [5]. 
A number of urinary biomarkers have been proposed for the detection of bladder cancer including 
tests based on miRNA [6], RNA [7], DNA [8], metabolites [9] and proteins [10]. The latter may be 
measured in exfoliated cells (e.g., ImmunoCyt®) or as soluble proteins in the urine e.g., NMP22 and 
BTA. Unfortunately, none of these tests are both highly specific and sensitive for early stage and low 
grade disease. Nucleic acid tests based on DNA methylation and mutations have the advantage over 
other biomarkers in identifying the presence of a disease-specific variant of the molecule that is being 
detected, rather than the total level of a molecule which may be released from both cancer and normal 
cells. Because bladder cancer is highly heterogeneous at the molecular level it is likely that a panel of 
biomarkers will be required to detect all tumours. Theoretically, highly specific markers can be 
combined to generate an effective test. However, total levels of protein markers may be influenced by 
non-malignant conditions and haematuria, limiting specificity and therefore suitability for inclusion in 
multimarker tests. A test based on bladder cancer-specific variants of proteins would be expected to 
outperform a test based on the total levels of these proteins. 
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Numerous proteomic approaches have been applied to analyse urine in the search for bladder cancer 
biomarkers (reviewed in [10]). The urinary proteome is challenging to mine in depth, in part due to an 
abundance of plasma proteins, and many proteomic studies have suggested plasma proteins as biomarkers 
despite the fact that they are unlikely to be specific for bladder cancer. For example, Chen et al. carried 
out quantitative shotgun proteomics on pooled bladder cancer urine samples and non-cancer controls 
using iTRAQ for relative quantitation, followed by MRM quantitation of candidate biomarkers 
producing a multimarker panel with a ROC AUC of 0.814 [11,12]. The “biomarkers”, however, are 
moderately abundant plasma proteins rather than cancer-specific proteins. Top-down approaches have 
the ability to detect proteoforms not readily distinguishable in bottom-up approaches. However, to 
date, CE-MS and MALDI based profiling have failed to generate a highly sensitive and specific test 
for bladder cancer [13–15]. A small number of studies have used lectin affinity chromatography in 
studies of the urinary glycoproteome, however these studies have used broad specificity lectins 
(expected to capture most glycoproteins) rather than focussing on alterations in glycosylation [16,17]. 
Kreunin et al. [16] compared the glycoproteome of urine from bladder cancer patients and non-cancer 
patients using Concanavalin A (ConA) affinity chromatography combined with nano-liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). Alpha-1ȕ-glycoprotein was identified as 
the most discriminatory protein, but again, this is a plasma protein. 
It has been reported that protein glycosylation is significantly altered in many cancers including 
bladder cancer [18]. Alterations in glycosylation patterns in cancer reflect changes in expression of 
glycosyltransferases and glycosidases [19]. The changes to glycan structure that can occur in cancer 
include O-glycan truncation, increased branching of N-glycans, and increased sialylation, sulfation and 
fucosylation [18]. There have been several studies on the glycosylation state of specific proteins found 
in the sera of cancer patients. For example, increased fucosylation and sialylation of PSA have been 
reported in prostate cancer [20]. Wu and colleagues used a fucose specific lectin, Aleuria aurantia 
lectin (AAL) to characterise the fucosylation of haptoglobin in ovarian cancer and found increased 
levels of fucosylated haptoglobin in patient sera [21]. Another study observed glycan-specific changes 
in periostin and thrombospondin in ovarian cancer [22]. All of these studies found that the specific 
protein glycoforms were able to better differentiate cancer sera from control serum samples than the 
total concentration of the protein. Perhaps the best example of a cancer specific glycoform is AFP-L3. 
An increase in total AFP concentration in the serum was originally used as an indicator for 
hepatocellular carcinoma (HCC); however, measuring the total AFP concentration cannot always 
discriminate between small HCCs and chronic liver disease. Further study of the protein identified a 
core-fucosylated form of AFP known as AFP-L3 which is specific to HCC and which can be measured 
in the serum to distinguish between HCC and chronic liver disease, making it a clinically useful 
biomarker [23]. Identifying a similarly cancer-specific glycoprotein biomarker for bladder cancer 
could be the answer to finding an accurate non-invasive test for disease detection and long-term 
surveillance of patients. 
In the experiments reported here we test the hypothesis that incorporating selective lectin 
chromatography into urinary proteomics workflows has the potential to uncover urinary biomarkers for 
bladder cancer. We focus on low grade non-invasive bladder cancer as this is the form of the disease 
which is most challenging to detect using currently available non-invasive tests. 
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2. Materials and Methods 
 
 
2.1. Materials and Cell Lines 
 
 
All lectins were purchased from Vector Laboratories Ltd. (Peterborough, UK). All other chemicals 
and materials were purchased from Sigma-Aldrich (St. Louis, MI, USA) unless otherwise stated. 
The bladder cancer cell lines 5637 and HB-CLS-2 were purchased from CLS Cell Lines Service 
GmbH (Eppelheim, Germany). NHU-TERT, VM-CUB-1, MGH-U3, RT4, RT112, SW780 and T24 
were provided by Professor Margaret Knowles (University of Leeds, Leeds, UK). The UROtsa cell 
line was a gift from Alexander Dowell (University of Birmingham, Birmingham, UK). Cell lines were 
cultured as previously described [24]. The bladder cancer cell lines were derived from tumours of 
different grades as detailed in Supplemental Table S1. Cell lysates were prepared by sonication in PBS 
containing cOmplete EDTA-free protease inhibitor cocktail followed by a 10 min centrifugation at 
13,000 rpm. The protein concentration of the supernatant was determined by Bradford assay. 
 
 
2.2. Patient Samples 
 
 
Patient urine and serum samples were collected as part of the Bladder Cancer Prognosis Programme 
(BCPP) [25]. Recruitment to BCPP was undertaken between 2005 and 2011 and consists of samples 
from patients with suspected primary bladder cancer. Midstream urine was collected, centrifuged at 
2000 rpm for 10 min and the supernatant stored in aliquots at í& After sample collection, each 
patient underwent TURBT and definitive diagnosis by histopathological examination of the resected 
tissue. Urine samples obtained from patients with non-malignant conditions were retained in the BCPP 
collection and have been used as non-cancer controls. For the lectin ELISA experiments, urine samples 
were pooled into four control pools (two normal and two from patients with cystitis or inflammation) 
and six cancer pools (two from each of stages pTa, pT1 and pT2+). For the proteomics experiments, 
two pools of pTa patient urine were used (n = 75; n = 36) and a non-cancer control urine pool (n = 28). 
All samples used were negative for haematuria by dipstick test. Further patient information is provided 
in Supplemental Materials. 
 
2.3. Lectin ELISAs 
 
 
Urine samples were diluted ×50 in PBS and cell lysates and serum samples were diluted to 3 ug 
protein/mL in PBS and 100 µL added to 96 well Maxisorb Immuno-plates followed by a 1 hour 
incubation at 37°C to adsorb proteins. The wells were washed three times with 200 ȝL PBS containing 
0.05% w/v Tween® 20 (PBST, Sigma-Aldrich). The plates were blocked with 1% BSA in PBS for one 
hour. After washing with PBST, 100 ȝ/ of biotinylated lectin at 10 ȝJP/ in PBS was added to the 
wells  and  incubated for  30  min.  After  washing  with  PBST,  100  ȝ/ of  a  1  in  200  dilution of 
streptavidin conjugated to horseradish peroxidase (R&D Systems, Abingdon, UK) in 1% BSA in PBS 
was added and incubated for 30 min. The plates were then washed five times with PBST and 100 ȝL of 
substrate solution ƍƍ-tetramethlbenzidine) was added. The reaction was stopped with 40 ȝL of 
2M H2SO4  and the absorbance measured at 450 nm. All ELISAs were performed in triplicate and 
means compared across experimental groups using t-tests. 
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2.4. Lectin Dot Blots 
 
 
Samples were diluted (cell lysate or serum diluted to 3 ug protein/mL in PBS and urine diluted ×50 
in PBS and 2 ȝ/ spotted onto nitrocellulose membrane. Once dry, the membrane was blocked with 1% 
BSA in PBS for 40 min and then washed three times with PBST. The membrane was incubated in a 
lectin solution at 10 ug/mL in PBS for 30 min, washed with PBST and incubated with streptavidin-HRP 
(as above). The membrane was washed with PBST and imaged using ECL and photographic film. 
 
2.5. Lectin Affinity Chromatography 
 
 
Lectin conjugated agarose beads were washed 10 times with PBS to remove sugars in their storage 
solution and 500 µL of 50% slurry mixed with 5 mL of pooled urine and 500 ȝ/ of 12 × PBS. Binding 
was allowed to occur during a 2 h incubation on a rotating mixer at 4°C. The beads were captured on 
filters and the flow through was collected and stored. The beads were then washed thoroughly with PBS 
and bound glycoproteins eluted with 2 × 400 ȝL of 100 mM L-fucose or 200 mM N-aceytl-D-galactosamine 
(GalNAc). In experiments using UEA1 and DBA (which require divalent cations) PBS was substituted 
with 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 100 uM MnCl2, 100 uM ZnSO4 and 20 mM MOPS, 
pH  7.4.  All lectin affinity-chromatography–shotgun-proteomics experiments were performed as  2 
independent replicates. 
 
2.6. Filter-Aided Sample Preparation and Tryptic Digestion 
 
 
Up to 200 µg of protein was dissolved in 9 M Urea, 1% CHAPS (Melford Laboratories, Ipswich, UK) 
in 100 mM triethylammonium bicarbonate (TEAB), and incubated with 20 mM dithiothreitol (DTT) 
for 30 min at room temp. Following addition of 50 mM iodoacetamide the proteins were captured in 
0.5 mL 30 kDa MWCO centrifugal filters, centrifuged at 13,000 rpm for five minutes and washed four 
times with 100 mM TEAB. Proteins were digested by incubating overnight at 37 °C with 5 ȝJ of 
sequencing grade trypsin (Promega). Peptides were collected by centrifugation. 
 
2.7. Stable Isotope Labelling 
 
 
After  tryptic  digestion,  formaldehyde  was  added  to  the  control  urine  peptides  to  a  final 
concentration of 0.2% w/v and deuterated formaldehyde was added to the pTa patient urine peptides. 
Sodium cyanoborohydride was added to both samples to a final concentration of 25 mM. After 30 min, 
0.5 M ammonium bicarbonate was added to quench the reaction. The control and cancer urine samples 
were then combined and acidified with 10% trifluoroacetic acid (TFA), the peptides were captured on 
a C18 cartridge, washed with 0.1% TFA and peptides eluted with 600 ȝ/ of 60% acetonitrile 
(ACN)/0.1% TFA. 
 
2.8. Peptide Fractionation and LC-MS/MS 
 
 
Peptides were dried and dissolved in mixed mode buffer A (110 ȝ/ 20 mM ammonium formate, 
pH 6.5, 3% ACN) and separated into 16 fractions using an Acclaim® Mixed-Mode WAX-1, 3 um, 120 Å 
(2.1 × 150 mm) column (Dionex, Camberley, UK) at a flow rate of 100 ȝ//min. The elution gradient 
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used was 0%–50% of buffer B (2 mM ammonium formate, pH 3.0, 80% ACN) for 45 min followed by 
50%–100% buffer B over five minutes and then 100%–0% buffer B for the last 10 min. Fractions were 
dried and reconstituted in 0.1% formic acid (FA) in water. The peptides in each fraction were analysed 
by LC-MS/MS using a 60 min gradient of 0%–36% ACN in 0.1% FA at a flow rate of 350 nL/min 
with an Acclaim® Pepmap C18, 3 ȝm, 100 Å column (25 cm × 75 ȝm) (Thermo Scientific, Loughborough, 
UK) attached to an Ultimate 3000 RS HPLC system coupled to an Impact Quadrupole-TOF mass 
spectrometer (Bruker Daltonics, Coventry, UK) working in data-dependent mode at 5 MS/MS per cycle. 
 
2.9. Peptide Identification and Analysis 
 
 
All MS/MS spectra were searched against a database containing Swissprot human sequences and 
randomized versions thereof using MASCOT (version 2.3 Matrix Science Ltd, London, UK). Search 
parameters were as follows: (i) species: Homo sapiens; (ii) enzyme: trypsin; (iii)  missed cleavages; 
(iv) 10 ppm precursor ion tolerance; (v) 0.02 Da fragment ion tolerance; (vi) fixed modifications: 
cysteine carbamidomethylation; (vii) variable modifications: methionine oxidation; (viii) a peptide 
score of >25. For quantitative experiments light and heavy dimethylation of N-termini and lysine 
residues were also included as variable modifications. Proteinscape 3 software (Bruker Daltonics) was 
used to combine multiple search results and filter the data using a protein false discovery rate of 1%. 
WARP-LC (Bruker Daltonics) was used for relative quantitation based on extracted ion chromatograms 
and limma used for statistical analysis of differential expression [26]. 
 
3. Results 
 
 
3.1. Lectin Binding to Urothelial Cell Line Lysates 
 
 
Lectin ELISAs were used to evaluate the ability of 25 different lectins to bind to cell lysates of 2 
normal urothelial human cell lines and 8 human bladder cancer cell lines derived from tumours of 
different grades (potentially allowing us to determine how glycosylation differs between low- and 
high-grade disease). Although different cell lines show quite different lectin binding profiles, none of 
the lectins showed consistent, substantially different binding between the normal and cancer cell lines 
or between cancer cell lines derived from low or high grade tumours (p > 0.05 in all cases). The data 
are summarised in Figure 1. Figure 2 demonstrates the specificity of AAL for fucose containing 
substrates: including 100 mM L-Fucose during the incubation of AAL on urothelial cell line lysate 
coated plates effectively prevents any binding from taking place. 
 
3.2. Lectin Binding Properties of Urinary Proteins 
 
 
The binding of the same panel of 25 lectins to the proteins in pooled urine from patients without 
bladder cancer or with pTa, pT1 or pT2+ bladder cancer was tested by ELISA. None of the lectins 
demonstrated a statistically significant higher or lower binding (p > 0.05) to the proteins in the urine of 
cancer patients relative to urine of non-cancer controls (Figure 3). 
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Figure 1. Lectin binding to urothelial cell lysates. Cell lines are shown from left to right, 
non-cancer (NHU-TERT & UROtsa), grade 1 (MGH-U3, RT4, SW780), grade 2 (RT112, 
VM-CUB-1, 5637) and grade 3 bladder cancer (T24, HB-CLS-2). The relative binding 
level of each lectin to the cell lines is shown on a sliding scale from high (red) to low (blue). 
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Figure 2. Fucose inhibition of AAL binding to cell lysates. Lectin ELISA results are 
shown for AAL binding (absorbance 450 nm) to cell lysates ±100 mM L-fucose. 
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Figure 3. Lectin binding to pooled urine samples. Each pooled urine samples consists of 
urine from >8 patients with: C1&C2 = no abnormality detected, C3&C4 = no malignant 
disease (cystitis/inflammation), Ta1 & Ta2 = pTa UBC, T1-1 &T1-2 = pT1 UBC, T2-1 & 
T2-2 = MIBC. The relative binding level of each lectin to the 8 pooled urines is shown on 
a sliding scale from high (red) to low (blue). 
 
3.3. Lectins with Selectivity for Urothelial Glycans Relative to Plasma Glycans 
 
 
A lectin that could enrich urothelial glycoproteins relative to plasma glycoproteins in urine would 
be a useful tool in urine proteomics. We therefore compared the binding of the 25 lectins to bladder 
cell line lysates with their binding to serum from non-cancer control subjects by lectin ELISA and 
confirmed selected results with lectin dot blots (Figure 4). Whilst RCA1 and PHA-E bound more 
strongly to serum than to cell lysate, the majority of lectins preferred the lysate with 10 lectins showing 
very low binding to serum. These lectins, in particular UEA1 and DBA, showed very high cell:serum 
binding ratios. Lectins that bind mannose, glucose or sialic acid tended to show low binding to 
urothelial glycans whereas fucose, galactose and N-acetylgalactosamine binding lectins exhibited high 
binding to urothelial glycans relative to serum. 
 
3.4. Glycoproteome Analysis of Pooled pTa UBC Patient Urine 
 
 
Shotgun proteomics was used to assess the ability of AAL, UEA and DBA affinity chromatography 
to extract subproteomes from a pooled bladder cancer urine sample (75 patients with G1-G3 pTa 
disease). UEA1 and DBA were chosen for glycoprotein enrichment due to their striking preference for 
urothelial  proteins  over  serum  proteins  and  AAL  was  chosen  because  it  not  only  displayed  a 
preference for urothelial proteins over serum proteins, but has previously been shown to have an 
affinity for cancer-related glycoproteins. LC-MS/MS analysis of the proteins bound to UEA1 or DBA 
and eluted with 100 mM L-fucose or 200 mM N-aceytl-D-galactosamine respectively identified 
surprisingly few proteins: DBA captured 140 proteins of which 75 were found in two experimental 
replicates and UEA1 captured 122 proteins of which 69 were common to both replicates. Furthermore, 
these proteins included keratins and abundant proteins such as uromodulin and albumin indicative of 
non-specific binding. In contrast, in both experimental replicates, more than 500 proteins were eluted 
from AAL with 100 mM L-Fucose. There was a high degree of overlap between the proteins identified 
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in the AAL eluates in both replicates with 436 protein identifications common to both (Figure 5). Of 
these 436 proteins, 285 contain glycosylation sites (65%). Of these 285 glycoproteins, 274 possess N- 
linked glycans and 24 possess O-linked glycans. 
 
 
 
Figure 4. Lectin binding to urothelial cell line lysates and serum. The histogram shows 
data from lectin ELISAs run in triplicate (pooled cell lysate and pooled serum). The inserted 
panel shows confirmatory dot blots. With the exception of PHA-E, SNA and LCA all 
lectins showed significantly different binding to lysates and serum (p < 0.05). 
 
AAL eluate duplicates Flow-through duplicates 
 
 
 
114 436 119 130 449 94 
 
 
 
 
 
161 275 174 
 
 
 
 
Figure 5. The number of proteins identified by LC-MS/MS in the AAL flow-through and 
eluted fractions. The upper Venn diagrams show the number of proteins identified in the 
flow-through and eluted fractions of two independent AAL chromatographies of a pooled 
urine sample from patients with pTa bladder cancer. The lower Venn diagram shows the 
overlap between the proteins identified in both eluates and both flow-throughs. 
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The AAL flow throughs (i.e., proteins not captured by AAL) were also analysed by LC-MS/MS and 
the protein identifications compared with the proteins identified in the AAL eluate to determine which 
proteins were enriched by the AAL affinity chromatography. We defined proteins as enriched by AAL 
if they were present in both eluates and were identified by at least twice as many peptides in the 
eluates as in the flow throughs. Using these criteria, AAL enriched 186 proteins. Of these 186 enriched 
proteins, 115 (62%) contain glycosylation sites and 84 of these proteins were not identified in the 
flow-throughs. Of the 186 enriched proteins, 70 are associated with the extracellular space and 71 with 
the plasma membrane. This suggests that AAL lectin affinity chromatography may be able to identify 
proteins originating from the urothelial cell surface or proteins released from the urothelium. The 
levels of abundant plasma proteins were decreased in the AAL eluates relative to the flow-thoughs: 
albumin decreased from 8307 peptide spectrum matches in the flow-throughs to 585 in the eluates and 
serotransferrin decreased from 950 to 76 peptide spectrum matches. Information on the protein 
identifications are provided in Supplemental Materials. 
 
3.5. Quantitative Comparison of AAL Binding Proteins in the Urine of Control Subject and Patients 
with G1 pTa Bladder Cancer 
 
AAL affinity chromatography was performed on pooled urine samples from patients with G1 pTa 
bladder cancer (n = 36) and non-cancer controls (n = 28). The eluted proteins were digested and the 
peptides stable isotope labelled as described in the method section, the samples combined and analysed 
by shotgun proteomics. Duplicate experiments again proved reproducible with 394 protein identified 
in both AAL eluates. We also analysed the 2 pooled urine samples without AAL enrichment in 
duplicate with 501 protein identifications common to replicates. The heavy/light peptide intensity 
ratios were used to estimate the relative levels of proteins in the two pooled urine samples in the AAL 
eluate  and  whole  urine  datasets.  In  the  AAL  eluates  the  concentrations  of  21  proteins  were 
significantly (p << 0.01) and substantially (-fold increase in both experimental replicates) higher in 
the pooled pTa urine than the control urine. Of these, 12 proteins were also increased in the cancer 
sample in the whole urine experiments whereas 9 of the proteins were increased in cancer only in the 
AAL eluates. The 12 proteins elevated in cancer in both the whole urine and AAL eluates are likely to 
be present at a higher total concentration in the cancer sample whereas the 9 proteins increased in the 
AAL eluates but not whole urine could be cancer specific glycoforms. Of the 9 proteins with apparent 
altered  glycosylation  (rather  than  simply  an  increase  in  total  concentration), 6  were  previously 
identified as released by bladder cancer cell lines in vitro [24] (mucin-1 (MUC1), golgi apparatus 
protein 1 (GLG1), endoplasmin (HSP90B1), prostatic acid phosphatase (ACPP), Ig gamma-2 chain C 
region (IGHG2), and deoxyribonuclease-2-alpha (DNASE2A)), and 3 were not (voltage-dependent 
anion-selective channel 1, carbonic anhydrase 1 and bile salt-activated lipase 11) . The cancer:normal 
intensity ratio in the AAL eluate and the whole urine data for the proteins previously identified as 
released by bladder cancer cell lines is shown in Figure 6. 
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Figure 6. AAL binding proteins and their cancer: normal peptide intensity ratios for the 
whole urine experiment and the AAL experiment. Mucin-1 (MUC1), endoplasmin 
(HSP90B1),  golgi  apparatus  protein  1  (GLG1),  prostastic  acid  phosphatase  (ACPP), 
Ig gamma-2 chain C region (IGHG2), and deoxyribonuclease-2-alpha (DNASE2A) all 
have a greater cancer: normal ratio after AAL enrichment. 
 
4. Discussion 
 
 
Current urinary protein biomarkers for bladder cancer lack the sensitivity and/or specificity required 
to have utility in the clinic. Aberrant glycosylation has been widely reported in cancer and some cancer 
biomarkers utilise changes in protein glycosylation to improve biomarker effectiveness. In this study 
we investigated whether cancer specific glycoforms are a feature of bladder cancer and whether lectin 
affinity chromatography is a useful tool in urine proteomics. In summary, the binding of 25 different 
lectins to bladder cancer cell lines or urine from control subjects and patients with bladder cancer did 
not detect any major global changes in glycosylation. We did, however, find that many lectins have a 
preference for bladder cancer cell line proteins over plasma proteins and this may be useful for 
discriminating between proteins that are released into the urine from the urothelium and those that are 
filtered through the kidney or leak in due to haematuria. 
A recent paper by Yang et al. reported that the binding of many lectins differed significantly between 
a normal urothelial cell line (HCV29) and several bladder cancer cell lines, and went on to show 
increased binding of LCA and SNA and decreased binding of ConA to bladder cancer tissue relative to 
adjacent normal tissue [27]. The use of different reference cell lines (NHU-TERT and UROtsa) in our 
study may be the reason that we did not see clear differences between the non-cancer and cancer cell 
lines, although differences between individual cell lines were observed. The lack of evidence for 
cancer-specific changes in glycosylation in our experiments does not exclude the possibility that they 
exist since we looked globally at the whole glycoproteome rather than determining the glycosylation 
status of individual proteins. The fact that no lectins demonstrated preferential binding to bladder 
cancer patient urine samples over control urine samples may reflect that the vast majority of the 
proteins in the urine samples are not tumour derived. Consistent with this finding, a recent study of 
urinary glycans found only small changes in the N- and O-linked glycomes of patients with bladder 
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cancer [28]. The literature on lectin binding to bladder cancer tissues is complex with no clear 
consensus as to which lectins bind preferentially to tumours over normal tissue or relationships of 
lectin binding to stage, grade and outcome [29,30]. These data indicate that specific glycoprotein 
markers will be required rather than global changes in glycosylation. 
Perhaps our most important finding is that several lectins are selective for urothelial proteins over 
plasma proteins. This is a useful characteristic for bladder cancer urine proteomics because low 
abundance urothelial proteins can be masked from detection by mass spectrometry by the presence of 
highly abundant serum proteins in the urine. The broad specificity lectins WGA and ConA that have 
been used in previous urinary glycoprotoemic studies [16,17] however, are not selective for urothelial 
proteins over plasma proteins. When we tested the ability of the 2 lectins with the greatest selectivity 
for urothelial proteins, UEA1 and DBA, to enrich urothelial glycoproteins from urine we identified 
only a small number of proteins. Perhaps these unexpected results are because the lectins recognise 
cellular proteins that are not released into the urine or because the eluting sugars were unable to 
effectively compete with the glycoprotein-lectin interaction. Nonetheless, it would seem that the other 
lectins with a high lysate/serum ratio (PNA, SJA, GSL I, SBA, PHA-L, STL, VVA) should be 
considered in urinary glycoproteomic workflows. AAL was selected in this study partly because it 
showed a small preference for urothelial proteins but more so because it has previously been used to 
enrich aberrantly glycosylated proteins in HCC [31]. AAL is specific for core and terminal fucose 
structures  including  fucose  (Į-1,6)  linked  to  N-acetylglucosamine  and  fucose  Į-1,3)  linked  to 
structures related to N-acetyllactosamine (85). The fucose Į-1,6) residue is a core fucose structure that 
is present in many mammalian tissues and has been reported to be altered in pathological settings. 
Of the 580 unique proteins captured by AAL, 6 behave as if they are aberrantly glycosylated 
in bladder cancer: mucin-1, golgi apparatus protein 1, prostatic acid phosphatase, endoplasmin, 
deoxyribonuclease-2-alpha and Ig gamma-2 chain C region. The selection was based on the fact that 
they are all released by bladder cell lines [24] and it appears that it is their glycosylation status rather 
than the total quantity of these proteins which change in bladder cancer. For two of these proteins, 
Deoxyribonuclease-2-alpha (DNASE2) and Ig gamma-2 chain C region (IGHG2) there is a lack of 
further evidence for a role in bladder. Endoplasmin (HSP90B1) is a ubiquitously expressed molecular 
chaperone of plasma membrane associated and secreted proteins [32]. Heat shock proteins are widely 
reported as overexpressed in cancer and one study reported that HSP90B1 is overexpressed in canine 
bladder cancer [33]. Prostatic acid phosphatase (ACPP) is a 100 kDa tyrosine phosphatase that 
dephosphorylates a diverse array of substrates under acidic conditions [34]. ACPP exists as intracellular 
and secreted forms that possess different glycosylation patterns and different hydrophobicities [35]. 
Although serum ACPP can be used to monitor prostate cancer it is reportedly not expressed in bladder 
cancer [36] and is not likely be a good biomarker for bladder cancer (because urinary ACPP may be 
primarily derived from the prostate) unless a genuinely bladder cancer specific glycoform exists. 
MUC1 and GLG1 appear to be the most interesting of the 6 candidates as discussed below. 
MUC1 is a transmembrane protein present in normal urothelium on the apical surfaces of umbrella 
cells and acts to protect the cells from adhesion of bacteria [37]. Overexpression and changes in 
glycosylation of MUC1 have been reported in lung, breast, ovary, colon and bladder cancer [38]. In an 
immunohistochemistry study of 539 bladder tumours MUC1 was expressed in 62% of the tumours and 
increased with tumour grade [39]. Serum levels of MUC1 are elevated in patients with late stage 
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bladder cancer but sensitivity for early disease is poor [38]. An investigation of urinary levels of 
MUC1 31 patients with TCC and 30 control patients found no significant difference between patient 
groups [40]. However, total MUC1 was measured whereas our data suggest that it is an alternatively 
glycosylated form of MUC1 that is increased in the urine of bladder cancer patients. 
The golgi apparatus protein 1 (GLG1), also known as CFR, ESL-1 and MG-160, is a 135 kDa 
glycosylated single pass type I transmembrane protein that contains 16 cysteine-rich GLG1 repeats [41]. 
It is found in the golgi apparatus and on the cell surface membrane. GLG1 is able to bind with many 
different proteins making it an important regulatory protein and signal transducer. The localisation 
of GLG1 is a crucial determinant of GLG1 function and is influenced by two mechanisms: the 
transmembrane domain and cytoplasmic tail retain GLG1 in the golgi apparatus, whereas the cys-rich 
repeats destabilise the protein and GLG1 is recruited to the cell surface via processes of stability 
control [41]. It has also been reported that GLG1 can be released from the cell by proteolytic cleavage 
at the juxtamembrane region [42]. These mechanisms of localisation and proteolytic cleavage may be 
altered in cancer and may play a role in the increased presence of GLG1 in the urine. GLG1 has been 
shown by immunohistochemistry to be highly or intermediately expressed in both high and low grade 
urothelial cancer tissue samples [43]; furthermore, GLG1 was detected on the cell surface of bladder 
cancer cell lines (Ward, unpublished data). Therefore, it seems plausible that the GLG1 detected in 
pTa patient urine is tumour derived. 
 
5. Conclusions 
 
 
Our data demonstrate a role for certain lectins in urinary biomarker discovery. The urinary 
glycoproteome has not been fully explored to date and using the lectins with a strong preference for 
urothelial proteins over serum proteins (Figure 4) in conjunction with shotgun proteomics may identify 
much needed biomarkers for bladder cancer. To assess the biomarker potential of the candidate 
glycoprotein biomarkers suggested by the current work, initial validation could be carried out by lectin 
affinity chromatography combined with an ELISA using specific antibodies against the target 
glycoprotein. If the glycoprotein concentration in urine samples from bladder cancer patients is 
confirmed as significantly greater than the concentration in control samples then a more streamlined 
assay such as a sandwich ELISA combining lectin and antibody binding would be required for full 
validation and ultimately clinical use. 
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